FR-ASSIST™ FOLR1 Ovarian Cancer IHC Testing Program
To support physicians in determining FRα expression in their ovarian cancer patients, ImmunoGen is providing a sponsored, no-charge, third-party IHC testing program for patients with a diagnosis of ovarian, fallopian tube, or primary peritoneal cancer.
Patient Eligibility Criteria:
Eligible patients may receive one (1) FOLR1 FDA (ELAHERE™) for Ovarian Carcinoma test at no cost regardless of test results or treatment decision. Patients must meet all of the following criteria to be eligible:
- Patient has ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer or primary fallopian tube cancer)
- Patient lives and receives treatment in the United States or a US Territory
- Patient does not have a known FRα expression from a previous test
- Patient has not previously been tested under this Program
Please note the program does not cover any other costs, including, but not limited to, office fees and biopsy fees. FOLR1 will be made available broadly to prescribers without regard to prescribing volumes or other commercial considerations.
To enroll your patient in the FOLR1 IHC Testing Program, download the FOLR1 test request form.
FAQ for Health Care Professionals
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients